[Among adults with cardiovascular disease and BMI≥27kg/m2 but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?] / Chez les adultes avec maladie cardiovasculaire et IMC≥27kg/m2, mais sans diabète, est-ce que le sémaglutide diminue le risque de mortalité cardiovasculaire, d'infarctus du myocarde ou d'AVC comparativement au placebo tout en étant sécuritaire ?
Rev Med Interne
; 45(3): 178-179, 2024 Mar.
Article
in Fr
| MEDLINE
| ID: mdl-38228454
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Stroke
/
Diabetes Mellitus, Type 2
/
Glucagon-Like Peptides
/
Myocardial Infarction
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
Fr
Journal:
Rev Med Interne
/
Rev. med. interne
/
Revue de medecine interne
Year:
2024
Document type:
Article
Country of publication:
France